Investors

BERKELEY HEIGHTS, NJ – May 15, 2008 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) has been invited to present at two investment banking conferences during May 2008. Both presentations will be webcast live and archived for 90 days on the Corporate Presentations page of the Cyclacel website at www.cyclacel.com

Rodman & Renshaw 5th Annual Global Healthcare Conference

Paul McBarron, Cyclacel’s EVP, Finance and COO, will present at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference to be held May 19-20, 2008, at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. The conference will feature presentations by 175 public and private healthcare-focused companies.

Cyclacel’s presentation will take place on Tuesday, May 20 at 3:20 p.m. local time (9:20 a.m. EDT) in the Atlantique Salon.

FBR Capital Markets 12th Annual Spring Investor Conference

Spiro Rombotis, Cyclacel’s President & Chief Executive Officer, will present at the FBR Capital Markets 12th Annual Spring Investor Conference to be held May 28-29, 2008 at the Grand Hyatt Hotel in New York City. The conference will feature presentations by approximately 200 public and private companies across a broad range of sectors including technology, media & telecom, healthcare and aerospace.

Cyclacel’s presentation will take place on Thursday, May 29 at 11:15 a.m. EDT in the Plymouth Room.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three Cyclacel drugs are in clinical development. Sapacitabine (CYC682), an orally-available cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly and cutaneous T-cell lymphoma (CTCL). Seliciclib (CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Several additional programs are at an earlier stage. Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair™ Cream for radiation dermatitis, Numoisyn™ Liquid and Numoisyn™ Lozenges for xerostomia. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology, oncology and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates.

Please visit www.cyclacel.com for additional information.  Note: The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.  Numoisyn™ and Xclair™ are trademarks of Sinclair Pharma plc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2007, as supplemented by the interim quarterly reports, filed with the SEC.